By Dr. Asnat Raziel, specialist in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal
Epigenetic reprogramming: what the first human trial showed
Epigenetic reprogramming is one of the boldest ideas in aging science. The goal is to give older cells back the “operating instructions” of young cells. Now, for the first time, the idea has moved from the lab into people. The US company Life Biosciences has reported the first data from a trial of a treatment called ER-100, given in the eye. Three patients with glaucoma received it, and all three tolerated it well. In addition, two of them showed improvement on a visual field test.
What is epigenetic reprogramming?
For example, every cell in the body carries the same DNA. Yet a skin cell and a nerve cell look and work completely differently. The difference comes from epigenetics, chemical marks on the DNA that decide which genes stay active. However, over the years these marks become disordered. As a result, cells gradually lose their identity and their function.
In 2006, the Japanese researcher Shinya Yamanaka discovered four genes that can return an adult cell to an embryonic-like state. Scientists call them the “Yamanaka factors”. However, a full return to an embryonic state is dangerous, because the cell loses its identity and may turn into a tumor. So researchers developed a partial, controlled version. It uses only three factors, OCT4, SOX2 and KLF4, and leaves out the fourth, c-MYC, because it can drive cancer.
From mice to people
The trial builds on a landmark study published in Nature in 2020 from Prof. David Sinclair’s lab at Harvard. The researchers delivered the three factors to nerve cells in the eyes of mice. As a result, the epigenetic marks returned to a younger pattern, and vision improved. In January, the FDA cleared the company to begin human testing. According to the company, this was the first treatment of its kind to receive such clearance.
How does ER-100 work?
Doctors give the treatment as a single injection into the eye. It uses a harmless virus called AAV as a genetic delivery vehicle that carries the genes into cells. The genes do not work on their own. They switch on only while the patient takes an antibiotic pill called doxycycline. In other words, doctors control when the treatment is active. In addition, patients received a tapering course of steroids to calm the immune response to the virus.
The study itself is an open-label phase 1 trial with no control group. Specifically, it includes two diseases of the optic nerve. The first is open-angle glaucoma. The second is NAION, a stroke of the optic nerve that is common after age 50 and has no approved treatment.
Epigenetic reprogramming in glaucoma: the results
The company presented the data on October 8 at an ophthalmology meeting in New Orleans. Three patients with glaucoma received the first dose level, 2×10¹¹ viral particles. They then took doxycycline daily for 8 weeks.
First, safety. All three patients tolerated the treatment well through day 56. There were no dose-limiting side effects and no serious adverse events. According to the company, all side effects were due to the injection, the steroids or existing conditions, not to the treatment itself.
Second, the first signs of benefit. Two of the three patients showed better visual field results on day 56. In each of them, at least 28% of the tested points improved by more than 4 decibels. Following these results, the safety board recommended moving to the second dose level, 6×10¹¹.
A note of caution: what the results do not show
Therefore, these very early data call for careful reading. First, only three patients received the treatment. Second, there is no control group, and both patients and doctors knew who got the treatment. Third, follow-up was short, just 56 days. Indeed, the company itself stresses that these findings cannot establish efficacy. In addition, there are no data yet on NAION patients, and no independent reviewers have checked the results yet.
Even so, this is a real milestone. For the first time, researchers have tested epigenetic reprogramming directly in the human body. The early data point to good short-term safety, which opens the way for further research.
Why epigenetic reprogramming matters for longevity medicine
The eye is a convenient starting point. It is a small, enclosed organ, doctors can inject it directly, and changes in function are easy to measure. But the big question is much broader. If cells really “remember” their young pattern, it may one day be possible to renew other tissues as well. This direction complements what we already know about drugs that may slow aging and about how aging cells damage tissues.
For now, our most effective tools remain simple: exercise, sleep, a balanced diet, a healthy weight and treatment of metabolic disease. You can read more about this in my article on what longevity medicine offers today.
The bottom line
So far, the first human trial of epigenetic reprogramming suggests the approach is safe in the short term in three patients. The visual field improvement in two of them is encouraging, but it is still far from proof. The next results, at a higher dose and in more patients, will show whether this is the start of a revolution or one more small step on a long road.
The information in this article is general only and is not a substitute for personal medical advice. For questions about your own health, please consult your doctor.
Sources
Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies
Reprogramming to recover youthful epigenetic information and restore vision
ER-100 in Optic Neuropathies – ClinicalTrials.gov NCT07290244
Life Biosciences Reports Initial Results from the First Reprogramming Trial
The developing company released the data, and they have not yet undergone peer review. The Hebrew version of this article is available here.
